Eugene John Vaios

Dr. Eugene John Vaios

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2023 in Cancers
Verified
Journal Article
Open access
PDF file
EVEugene John Vaios
Eugene John Vaios
SWSebastian Friedrich Winter
Sebastian Friedrich Winter
HSHelen A. Shih
Helen A. Shih
JDJorg Dietrich
Jorg Dietrich
KPKatherine B. Peters
Katherine B. Peters
ZRZachary J Reitman
Zachary J Reitman
Radiation necrosis, also known as treatment-induced necrosis, has emerged as an important adverse effect following stereotactic radiotherapy (SRS) for brain metastases. The improved survival of patients with brain metastases and increased use of combined systemic therapy and SRS have contributed to a growing incidence of necrosis. The cyclic GMP-AMP (cGAMP) synthase (cGAS) and stimulator of interferon genes (STING) pathway (cGAS-STING) represents a key biological mechanism linking radiation-induced DNA damage to pro-inflammatory effects and innate immunity. By recognizing cytosolic double-stranded DNA, cGAS induces a signaling cascade that results in the upregulation of type 1 interferons and dendritic cell activation. This pathway could play a key role in the pathogenesis of necrosis and provides attractive targets for therapeutic development. Immunotherapy and other novel systemic agents may potentiate activation of cGAS-STING signaling following radiotherapy and increase necrosis risk. Advancements in dosimetric strategies, novel imaging modalities, artificial intelligence, and circulating biomarkers could improve the management of necrosis. This review provides new insights into the pathophysiology of necrosis and synthesizes our current understanding regarding the diagnosis, risk factors, and management options of necrosis while highlighting novel avenues for discovery.

25 November 2025 in The Lancet Oncology
Verified
Journal Article
Closed access
TDTarek Bou Dargham
Tarek Bou Dargham
SWSebastian F Winter
Sebastian F Winter
KBKristen Batich
Kristen Batich
KGKarin Gehring
Karin Gehring
MPMichael W Parsons
Michael W Parsons
EVEugene John Vaios
Eugene John Vaios

1 June 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PSPaul W. Sperduto
Paul W. Sperduto
KMKathryn E. Marqueen
Kathryn E. Marqueen
ECEnoch Chang
Enoch Chang
JLJing Li
Jing Li
MDMichael A Davies
Michael A Davies
MMMinesh p Mehta
Minesh p Mehta
PURPOSE: Survival for patients with melanoma has recently improved. The propensity of melanoma to metastasize to the brain remains a common and serious feature of this disease. The purposes of this study were to evaluate prognostic factors for patients with newly diagnosed melanoma brain metastases (MBMs) in a large cohort treated with modern multimodal therapies, compare those results with those in prior eras, and update the Melanoma Graded Prognostic Assessment (GPA). METHODS: Univariable and multivariable (MVA) analyses of prognostic factors and treatments associated with survival were performed on 1,796 patients with newly diagnosed MBM treated between January 01, 2015, and December 31, 2021, using a multi-institutional retrospective database. Multiple imputation was used to address missingness of potential predictors. Significant variables in combined MVA were used to update the Melanoma GPA. Comparisons were made with legacy cohorts. RESULTS: Median survivals for cohorts A (1985-2007, n = 481), B (2006-2015, n = 823), and C (2015-2021, n = 1,796) were 6.7, 9.8, and 16.6 months and median follow-up times were 40.1, 43.6, and 48.8 months, respectively. In combined MVA, significant prognostic factors for survival were higher Karnofsky Performance Status, fewer MBMs, absence of extracranial metastases, lower serum lactate dehydrogenase, and no immunotherapy before MBM. These factors were incorporated into the updated Melanoma GPA. The combined median and 3-year survivals for patients with GPA 0-1, 1.5-2, and 2.5-4.0 were 5.4, 13.2, and 43.2 months and 12.4%, 28.8%, and 51.6%, respectively. CONCLUSION: Prognostic factors have changed and survival has improved for patients with MBM but varies widely by GPA. The updated Melanoma GPA calculator (BrainMetGPA), available free online, can be used to estimate survival, individualize treatment, stratify clinical trials, guide surveillance, and augment clinical trial eligibility. Multidisciplinary treatment is essential. Trials are needed to elucidate the optimal sequencing of various therapeutic modalities.

15 February 2023 in Neurosurgery
Verified
Journal Article
Closed access
AHAden P. Haskell-Mendoza
Aden P. Haskell-Mendoza
ESEthan S. Srinivasan
Ethan S. Srinivasan
ELEmily C. Lerner
Emily C. Lerner
RERyan M. Edwards
Ryan M. Edwards
ASAllison M. Schwalb
Allison M. Schwalb
Peter FecciPeter Fecci
Peter Fecci
BACKGROUND: The management of intracranial oncological disease remains a significant challenge despite advances in systemic cancer therapy. Laser interstitial thermal therapy (LITT) represents a novel treatment for local control of brain tumors through photocoagulation with a stereotactically implanted laser fiber. Because the use of laser interstitial thermal therapy continues to increase within neurosurgery, characterization of LITT is necessary to improve outcomes. OBJECTIVE: To quantify the risk of tumor seeding along the laser fiber tract in patients receiving LITT for primary or metastatic brain tumors at a high-volume treatment center. METHODS: We retrospectively reviewed all patients receiving LITT from 2015 to 2021 at our medical center. Patients with biopsy-confirmed tumors were included in this study. Tract seeding was identified as discontinuous, newly enhancing tumor along the LITT tract. RESULTS: Fifty-six patients received LITT for biopsy-confirmed tumors from 2015 to 2021, with tract seeding identified in 3 (5.4%). Twenty-nine (51.8%) patients had gliomas, while the remainder had metastases, of which lung was the most common histology (20 patients, 74%). Tract seeding was associated with ablation proceeding inward from superficial tumor margin closest to the cranial entry point (P = .03). Patients with tract seeding had a shorter median time to progression of 1.1 (0.1-1.3) months vs 4.2 (2.2-8.6) months (P = .03). CONCLUSION: Although the risk of tract seeding after LITT is reassuringly low, it is associated with decreased progression-free survival. This risk may be related to surgical technique or experience. Follow-up radiosurgery to the LITT tract has the potential to prevent this complication.

29 March 2022 in Oncotarget
Verified
Journal Article
Open access
PDF file
EVEugene John Vaios
Eugene John Vaios
KBKristen A. Batich
Kristen A. Batich
ABAnne F. Buckley
Anne F. Buckley
ADAnastasie Dunn-Pirio
Anastasie Dunn-Pirio
MPMallika P. Patel
Mallika P. Patel
KPKatherine B. Peters
Katherine B. Peters
Https://doi.org/10.18632/oncotarget.28222 Eugene J. Vaios, Kristen A. Batich, Anne F. Buckley, Anastasie Dunn-Pirio, Mallika P. Patel, John P. Kirkpatrick, Ranjit Goudar, Katherine B. Peters

10 December 2025 in Neuro-Oncology Practice
Verified
Journal Article
Closed access
AGAriel T Gonzalez
Ariel T Gonzalez
AHAden P Haskell-Mendoza
Aden P Haskell-Mendoza
EREllery H Reason
Ellery H Reason
JJJoshua D Jackson
Joshua D Jackson
CWChunhao Wang
Chunhao Wang
Peter FecciPeter Fecci
Peter Fecci
Background: Stereotactic radiosurgery (SRS) remains the standard of care for brain metastases (BM), offering effective local control with fewer neurocognitive side effects. However, distinguishing radiation necrosis (RN) from local recurrence (LR) is challenging in lesions that enlarge post-SRS. Identifying clinical and treatment-related factors associated with RN vs LR may improve decision-making. Prior smaller studies have suggested time to progression may help differentiate RN from LR; we aimed to reassess this observation and explore other factors in a larger cohort. Methods: We retrospectively analyzed patients treated with SRS for BM between 2011 and 2022 who later underwent biopsy, with or without LITT, for imaging-suspected RN vs LR. Data included demographics, clinicopathologic characteristics, SRS-treatment parameters, and biopsy results. Results: Among the identified 145 patients with 151 progressive lesions, biopsy confirmed RN in 93 (61.6%) and LR in 58 (38.4%). A subset of lesions (n = 108) had complete dosimetric data. Median age at SRS was 62 years, with a median SRS-biopsy interval of 13 months. The median prescribed dose was 20 Gy for single-fraction and 27.5 Gy for hypofractionated regimens. Multivariable models identified age ≥65 and SRS to biopsy interval ≥9 months as predictors of RN in the full cohort. In the subset group with detailed dosimetric data, V12Gy ≥ median (4.64 cm³) additionally predicted RN and improved model fit. Conclusion: We identified older age, a longer SRS to biopsy interval, and higher V12Gy as predictors of RN. Our predictive models incorporate these variables and may support clinical decision-making, improve diagnostic accuracy, and optimize patient outcomes.